CEO Vas Narasimhan highlighted Novartis' strong performance in Q4 2024, with sales increasing 16% and core operating income ...

With its Q4 2024 financials on Friday, Novartis (NYSE:NVS) (OTCPK:NVSEF) indicated a delayed timeline for initial data from a Phase 3 trial for a cardiac therapy it co-develops with Ionis ...

Another wave of layoffs will impact Novartis‘ U.S. headquarters in New Jersey. In a filing with the state Department of Labor & Workforce Development, the East Hanover-based Swiss pharmaceutical ...

TOKYO, March 17 (Reuters) - Swiss pharmaceutical giant Novartis (NOVN.S), opens new tab will watch "very carefully" how the reciprocal tariff policy proposed by the United States unfolds in early ...

Entresto, approved in heart failure since 2015, has long been one of Novartis’ top growth drivers, bringing home $4.05 billion in U.S. sales in 2024. That said, a key combination patent on the ...

In 2022, Novartis said it would cut 8,000 jobs globally, Reuters reported, which would save the company $1 billion over the next two years Global drugmaker Novartis will lay off 427 employees who ...

Novartis signed on to become the National Football League’s first-ever corporate pharmaceutical partner. As part of the new multi-year deal, the Swiss pharma giant said it aims to empower ...

A federal court rejected Novartis Pharmaceuticals’, a unit of Novartis AG (NYSE:NVS) legal challenge to the Medicare Drug Price Negotiation Program, ruling that the program does not violate ...